Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Stock Information for Repare Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Repare Therapeutics Inc.

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results
Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025
Repare Therapeutics Announces Leadership Transitions
Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.